Zobrazeno 1 - 10
of 137
pro vyhledávání: '"U. Machein"'
Autor:
Thomas Bardin, Alexander So, Karine Lheritier, Mark Bloch, Rieke Alten, Naomi Schlesinger, Guido Junge, U. Machein
Publikováno v:
Annals of the Rheumatic Diseases. 74:544.1-544
Background Efficacy and safety of canakinumab (CAN) in frequently flaring difficult-to-treat gouty arthritis (GA) patients (pts) in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective has been published previously. Here, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3742de558edac3b62df02f39dd9afac3
https://doi.org/10.1136/annrheumdis-2015-eular.2199
https://doi.org/10.1136/annrheumdis-2015-eular.2199
Autor:
A. Kivitz, Guido Junge, Jacques P. Brown, P. Sunkureddi, E. Toth, Karine Lheritier, U. Machein, R. Möricke
Publikováno v:
Annals of the Rheumatic Diseases. 74:1209.4-1210
Background Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options and need effective alternative treatments. Canakinumab (CAN), a selective, human, anti-interleukin-1β monoclonal antibody,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04ee96dfa2fd03b14c1ec10982d257bf
https://doi.org/10.1136/annrheumdis-2015-eular.4396
https://doi.org/10.1136/annrheumdis-2015-eular.4396
Autor:
U. Machein, Rieke Alten, Naomi Schlesinger, Karine Lheritier, Mark Bloch, Schumacher Hr, Dominik Richard, Thomas Bardin, Alexander So
Publikováno v:
Annals of the Rheumatic Diseases. 73:785.2-785
Background There is a medical need for effective alternate treatments for acute gouty arthritis (GA) patients (pts) with frequent GA attacks in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective. 1 Canakinumab (CAN), a se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68c17748fe546821f6edc6e2f8683de1
https://doi.org/10.1136/annrheumdis-2014-eular.1807
https://doi.org/10.1136/annrheumdis-2014-eular.1807
Autor:
Pierre Quartier, I Kone-Paut, Luca Cantarini, Steven J. Spalding, Andrew Zeft, Sinisa Savic, Anna Simon, Rolando Cimaz, U. Machein, Ahmet Gül, Avi Livneh, Véronique Hentgen, Ivan Foeldvari, Helen J. Lachmann, Tilmann Kallinich, J. B. Kuemmerle-Deschner, S Ozen, J Frenkel, Philip J. Hashkes
Publikováno v:
Annals of the Rheumatic Diseases. 73:106.1-106
Background Due to low incidence rates, treatment data and guidelines in hereditary periodic fevers are limited. To complement published data from the autoinflammatory diseases PRINTO/Eurofever registry, an international noninterventional study of col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77ef20e0f8e25e078b67d9dcecdf4f8e
https://doi.org/10.1136/annrheumdis-2014-eular.3251
https://doi.org/10.1136/annrheumdis-2014-eular.3251
Publikováno v:
Transplantation proceedings. 33(7-8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e335aa629a750b580435aa7fae006c
https://pubmed.ncbi.nlm.nih.gov/11750475
https://pubmed.ncbi.nlm.nih.gov/11750475
Publikováno v:
Journal of neurochemistry. 73(5)
Interleukin-6 (IL-6) is involved in the pathophysiology of various diseases of the CNS. Because the molecular mechanism of action of this cytokine in human neurons is not well understood, we were interested in characterizing and defining a model syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bf4b8cc0e2680aa3c4bc14a3472f85e1
https://pubmed.ncbi.nlm.nih.gov/10537060
https://pubmed.ncbi.nlm.nih.gov/10537060
Autor:
Annette Damert, Georg Breier, Volker Rönicke, W. Risau, M R Machein, Karl H. Plate, J. Kullmer, U Machein, M Krieg
Publikováno v:
ResearcherID
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a mitogen and chemotactic factor for endothelial cells in vitro and an angiogenesis and vascular permeability factor in vivo. Due to its properties, VEGF is a candidate for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08621f19179d17ad90e01eb38d452472
https://pubmed.ncbi.nlm.nih.gov/10215998
https://pubmed.ncbi.nlm.nih.gov/10215998
Autor:
Dibdiakova, Katarina1,2 (AUTHOR) katarina.dibdiakova@uniba.sk, Majercikova, Zuzana1 (AUTHOR) majercikova.zuz@gmail.com, Galanda, Tomas3 (AUTHOR) tgalanda@imafexbb.sk, Richterova, Romana4 (AUTHOR) richterova.romana@uniba.sk, Kolarovszki, Branislav4 (AUTHOR) branislav.kolarovszki@uniba.sk, Racay, Peter1 (AUTHOR) peter.racay@uniba.sk, Hatok, Jozef1 (AUTHOR) jozef.hatok@uniba.sk
Publikováno v:
International Journal of Molecular Sciences. Mar2024, Vol. 25 Issue 5, p2858. 14p.
Autor:
U, Machein, W, Conca
Publikováno v:
Advances in experimental medicine and biology. 421
Matrix metalloproteinases (MMP) are a family of structurally related endopeptidases that resorb macromolecules of the extracellular matrix (ECM). They are involved in normal tissue remodeling and wound repair as well as in pathological processes such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee55b42742da039c761bb883efa12446
https://pubmed.ncbi.nlm.nih.gov/9330704
https://pubmed.ncbi.nlm.nih.gov/9330704
Publikováno v:
Fortschritte der Medizin. 113(3)
In 59 healthy subjects of different age groups with no signs of inflammatory processes, the basal II-6 levels were measured. The II-6 concentrations were significantly higher in the oldest group (66-90 years) than in the two other age groups (24-40,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3d7cdd287cb09aac6e5d3d2b9f05dc8c
https://pubmed.ncbi.nlm.nih.gov/7534257
https://pubmed.ncbi.nlm.nih.gov/7534257